CPX-351, a novel liposomal encapsulation of daunorubicin and cytarabine, improved long-term overall survival and remission versus conventional 7+3 chemotherapy in a population of adults …

2018年9月10日 · Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent …

Liposomal cytarabine-daunorubicin is 1 drug made up of 2 chemotherapy drugs: cytarabine. These drugs are combined into tiny particles called liposomes. The liposomes help the drugs …

2021年1月6日 · CPX-351 was associated with a superior overall response rate (ORR) and overall survival (OS) compared with classical 7+3 (cytarabine and daunorubicin) intensive …

2024年12月13日 · CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is an approved therapy for newly diagnosed therapy-related …

2018年7月19日 · CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal …

2023年11月2日 · CPX-351 treatment showed median overall survival (mOS) of 12.20 months, CR rate of 43.66%, and an overall remission rate (ORR) of 51.1%. Hematopoietic Stem Cell …

Liposomal daunorubicin and cytarabine is a type of chemotherapy combination. It is also known as CPX351 and L-DA. You pronounce daunorubicin as daw-noh-roo-bih-sin and cytarabine as …

CPX-351 is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. Primary analysis of the phase 3 trial in adults aged 60-75 years with newly …

2022年10月26日 · CPX-351 (Europe: Vyxeos ® liposomal; United States: Vyxeos ®) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. In …